文献速递关节外科

强效抗凝不降低高危患者静脉血栓栓塞症发生率

Potent Anticoagulation Does Not Reduce Venous Thromboembolism in High-Risk Patients.
PubMed 文献 · J Bone Joint Surg Am · 2019-01-01

基于2000至2015年60,467例初次及翻修全关节置换术的多中心回顾性研究,比较阿司匹林、低分子肝素和华法林的静脉血栓栓塞症预防效果。倾向评分匹配分析显示,在全膝关节置换术中,低分子肝素和华法林较阿司匹林增加静脉血栓栓塞症风险;在全髋关节置换术中,华法林增加高危患者风险,低分子肝素增加标准风险患者风险。华法林组假体周围感染率更高。

要点

  • 全膝关节置换术中,低分子肝素和华法林较阿司匹林增加静脉血栓栓塞症风险,标准风险和高危患者均如此。
  • 初次全髋关节置换术中,华法林增加高危患者静脉血栓栓塞症风险,低分子肝素增加标准风险患者风险。
  • 华法林组假体周围感染率高于阿司匹林组和低分子肝素组(P < 0.001)。

核心结论

  • 高危患者使用华法林和低分子肝素并不一定降低症状性静脉血栓栓塞症发生率。
  • 高危患者使用阿司匹林似乎与强效抗凝同样有效,且比华法林更有效。

研究设计与样本

  • 回顾性、多机构研究,纳入2000至2015年60,467例初次和翻修全关节置换术。
  • 根据26个变量计算静脉血栓栓塞症风险评分,评估90天症状性静脉血栓栓塞症和假体周围感染率。
  • 采用1:1倾向评分匹配及全样本逻辑回归分析。

主要发现

  • 阿司匹林预防在所有风险评分中均显示深静脉血栓、肺栓塞和静脉血栓栓塞症发生率低于华法林和低分子肝素单药。
  • 倾向评分匹配分析中,全膝关节置换术标准风险和高危患者中,低分子肝素和华法林较阿司匹林增加静脉血栓栓塞症风险。
  • 初次全髋关节置换术中,华法林增加高危患者静脉血栓栓塞症风险,低分子肝素增加标准风险患者风险。
  • 华法林组假体周围感染率高于阿司匹林组和低分子肝素组(P < 0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Based on current guidelines from the American Academy of Orthopaedic Surgeons (AAOS), a number of prophylactic modalities for the prevention of venous thromboembolism in total joint arthroplasty may be used. It is common practice that more potent prophylactic agents are used for patients at higher risk of venous thromboembolism. However, we are aware of no studies that have investigated the efficacy of potent anticoagulation in higher-risk individuals. Therefore, the purpose of our study was to test the hypothesis that low-molecular-weight heparin and warfarin result in a reduction in venous thromboembolism events in high-risk patients. METHODS: A retrospective, multi-institutional study of 60,467 primary and revision total joint arthroplasties from 2000 to 2015 was performed. Identified medications were classified as aspirin, low-molecular-weight heparin, or warfarin. Patients with unavailable venous thromboembolism prophylaxis information or those not receiving the aforementioned prophylaxis were excluded. Information pertinent to the objective of this study was collected and a venous thromboembolism risk score was calculated based on 26 variables. Treatment outcomes assessed included 90-day rate of symptomatic venous thromboembolism and periprosthetic joint infection. Propensity score matching was performed (1:1), as well as logistic regression analysis on the total sample. RESULTS: Aspirin prophylaxis demonstrated a lower rate of deep vein thrombosis, pulmonary embolism, and venous thromboembolism than warfarin and low-molecular-weight heparin alone throughout all risk scores. In the matched propensity score analysis, low-molecular-weight heparin and warfarin demonstrated increased odds of venous thromboembolism for both standard-risk and high-risk patients undergoing total knee arthroplasties compared with aspirin. For primary total hip arthroplasty, warfarin demonstrated an increased risk for high-risk patients and low-molecular-weight heparin demonstrated an increased risk for standard-risk patients. The prevalence of periprosthetic joint infection was higher in patients receiving warfarin (p < 0.001 for both comparisons of warfarin with aspirin and low-molecular-weight heparin). CONCLUSIONS: The results of this multi-institutional study demonstrate that the use of warfarin and low-molecular-weight heparin in higher-risk patients does not necessarily result in a reduction in symptomatic venous thromboembolism. Aspirin administered to higher-risk patients seems to be as effective as potent anticoagulation and more effective than warfarin. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Tan TL, Foltz C, Huang R, et al. Potent Anticoagulation Does Not Reduce Venous Thromboembolism in High-Risk Patients. J Bone Joint Surg Am. 2019. PMID: 30946192. doi:10.2106/JBJS.18.00335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。